Hodgkin's lymphoma natural history, complications and prognosis

Jump to navigation Jump to search

Hodgkin's lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hodgkin's lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray Findings

CT

MRI

Ultrasound

Biopsy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hodgkin's lymphoma natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hodgkin's lymphoma natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hodgkin's lymphoma natural history, complications and prognosis

CDC on Hodgkin's lymphoma natural history, complications and prognosis

Hodgkin's lymphoma natural history, complications and prognosis in the news

Blogs on Hodgkin's lymphoma natural history, complications and prognosis

Directions to Hospitals Treating Hodgkin's lymphoma

Risk calculators and risk factors for Hodgkin's lymphoma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2] Mohsen Basiri M.D.

Overview

Hodgkin's lymphoma has a bimodal age distribution and both children and adult may be affected. The early peak occurs in the middle-to-late 20s and the second peak after age 50 years. Treatment outcomes of Hodgkin’s lymphoma are excellent and five-year survival rates are more than 80%. Owing to modern therapies, the natural history of untreated Hodgkin’s lymphoma is actually difficult to determine. Survivors are at risk for relapse, second primary malignancies, cardiovascular complications and other treatment-related toxicities. Prognosis is based on the stage of the disease and other prognostic factors. The early stage of the Hodgkin's lymphoma is associated with the most favorable prognosis. The 5-year survival rate of patients with Hodgkin's lymphoma varies with the stage of the disease.

Natural History

  • Hodgkin's lymphoma has a bimodal age distribution and both children and adult may be affected. The most common symptom of classic Hodgkin's lymphoma includes painless localized peripheral lymphadenopathy.
  • Owing to modern therapies, the natural history of untreated Hodgkin’s lymphoma is actually difficult to determine.

Complications

  • The main complications of Hodgkin lymphoma are due to side effects of chemotherapy and/or radiotherapy, table below provides these general side effects:
Complications of Medical Therapy
Complications of Chemotherapy[2] Complications of Radiotherapy[2]
Skin reactions Skin changes
Nausea and vomiting Nausea and vomiting
Sore throat and painful swallowing Sore mouth
Taste changes Loss of appetite
Fatigue Fatigue
Diarrhea Diarrhea
Bone marrow suppression Bone marrow suppression
Dental cavities Constipation
Thyroid problems Hair loss
Fertility problems Cystitis
Heart and lung problems Muscle and joint pain
Second cancers Second cancers
Pain at the injection site
Inflammation of the vein
Allergic reactions
Organ damage
Fluid retention
  • Leading complications which cause of death in Hodgkin lymphoma survivors are second primary malignancies and cardiovascular toxicities. Cardiovascular complications of radiation therapy (RT) include pericarditis, myocardial ischemia or infarction, cardiomyopathy, heart failure, valvular abnormalities, or conduction abnormalities. [3][4]
  • Breast, lung, and colon cancer are the majority of second cancers in Hodgkin’s lymphoma survivors. [5]
  • Leukemia and non-Hodgkin lymphoma (NHL) are less common. Most leukemias that occur after the treatment are acute myeloid leukemia (AML) related to alkylating agent exposure. [6]
  • The relative risk of non-Hodgkin lymphoma increases among Hodgkin lymphoma survivors, and this rise increases with follow-up time. [7] [8]

Prognosis

Prognostic factors for early (Stage I and II) Hodgkin's lymphoma[9]

  • Hodgkin's lymphoma are divided into favorable and unfavorable groups based on prognostic factors.
  • Early favorable Hodgkin's lymphoma
  • Early favorable Hodgkin's lymphoma means that no factors listed below are present.
  • Early unfavorable Hodgkin's lymphoma
  • Early unfavorable Hodgkin's lymphoma means that one or more of the following factors are present:
  • Bulky disease
  • Larger than one-third the width of the chest
  • At least 10 cm in its greatest dimension in areas other than the chest
  • Presence of extra nodal disease (in areas other than the lymph nodes)
  • 3 or more areas of lymph node involvement
  • Erythrocyte sedimentation rate (ESR) of 50 mm/h or higher
  • Mixed cellularity Hodgkin's lymphoma
  • Presence of B symptoms
  • Unexplained fever over 38°C
  • Drenching night sweats
  • Unexplained weight loss – loss of more than 10% of original body weight within the last 6 months

Prognostic factors in advanced (stage III and IV) Hodgkin's lymphoma[10]

  • The International Prognostic Factors Project (IPFP) has developed an international prognostic score (IPS) based on 7 adverse factors for advanced (stage III and IV) Hodgkin's lymphoma. The factors that are present are combined to give a single score between 0 and 7.
  • Advanced favorable Hodgkin's lymphoma
  • Advanced favorable Hodgkin's lymphoma means that 0 to 3 factors listed below are present.
  • Advanced unfavorable Hodgkin's lymphoma
  • Advanced unfavorable Hodgkin's lymphoma means that 4 or more of the following factors are present:
  • Stage IV disease
  • Age 45 years or older
  • Male sex
  • Albumin level less than 4.0 g/dL
  • Hemoglobin level less than 10.5 g/dL
  • White blood cell (WBC) count at least 15,000/mm3
  • Lymphocyte count less than 600/mm3 or less than 8% of the total WBC count

5-Year Survival

  • Between 2004 and 2010, the 5-year relative survival of patients with Hodgkin's lymphoma was 87.7%.[11]
  • When stratified by age, the 5-year relative survival of patients with Hodgkin's lymphoma was 90.5% and 52.8% for patients <65 and ≥ 65 years of age respectively.[11]
  • The survival of patients with Hodgkin's lymphoma varies with the stage of the disease. Shown below is a table depicting the 5-year relative survival by the stage of Hodgkin's lymphoma:[11]
Stage 5-year relative survival (%), (2004-2010)
All stages 85.3%
Localized 90.8%
Regional 92.1%
Distant 76.2%
Unstaged 80.7%
  • The survival of patients with Hodgkin's lymphoma also varies with the subtype of Hodgkin's lymphoma. Shown below is the 5-year relative survival by the subtype of Hodgkin's lymphoma:[11]
    • Classical Hodgkin's lymphoma: 84.8%
      • Lymphocyte-rich: 87.1%
      • Mixed cellularity: 80%
      • Lymphocyte-depleted: 56.6%
      • Nodular sclerosis: 89.4%
      • Classical Hodgkin's lymphoma not otherwise specified: 75.2%
    • Nodular lymphocyte predominant Hodgkin's lymphoma: 95.3%
  • Shown below is an image depicting the 5-year conditional relative survival (probability of surviving in the next 5-years given the cohort has already survived 0, 1, 3 years) between 1998 and 2010 of Hodgkin's lymphoma by stage at diagnosis according to SEER. These graphs are adapted from SEER: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.[11]

5-year conditional relative survival (probability of surviving in the next 5-years given the cohort has already survived 0, 1, 3 years) of Hodgkin's lymphoma by stage at diagnosis according to SEER.

References

  1. Greco, Ralph S. (1974). "Hodgkin Disease in Connecticut From 1935 to 1962". Archives of Internal Medicine. 134 (6): 1039. doi:10.1001/archinte.1974.00320240073007. ISSN 0003-9926.
  2. 2.0 2.1 Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/treatment/?region=ab Accessed on September 10, 2015
  3. Shira L. Galper, James B. Yu, Peter M. Mauch, Jon F. Strasser, Barbara Silver, Ann Lacasce, Karen J. Marcus, Mary Ann Stevenson, Ming Hui Chen & Andrea K. Ng (2011). "Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation". Blood. 117 (2): 412–418. doi:10.1182/blood-2010-06-291328. PMID 20858859. Unknown parameter |month= ignored (help)
  4. Andrea K. Ng, Ann LaCasce & Lois B. Travis (2011). "Long-term complications of lymphoma and its treatment". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29 (14): 1885–1892. doi:10.1200/JCO.2010.32.8427. PMID 21483015. Unknown parameter |month= ignored (help)
  5. Michael Schaapveld, Berthe M. P. Aleman, Anna M. van Eggermond, Cecile P. M. Janus, Augustinus D. G. Krol, Richard W. M. van der Maazen, Judith Roesink, John M. M. Raemaekers, Jan Paul de Boer, Josee M. Zijlstra, Gustaaf W. van Imhoff, Eefke J. Petersen, Philip M. P. Poortmans, Max Beijert, Marnix L. Lybeert, Ina Mulder, Otto Visser, Marieke W. J. Louwman, Inge M. Krul, Pieternella J. Lugtenburg & Flora E. van Leeuwen (2015). "Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma". The New England journal of medicine. 373 (26): 2499–2511. doi:10.1056/NEJMoa1505949. PMID 26699166. Unknown parameter |month= ignored (help)
  6. J. M. Kaldor, N. E. Day, E. A. Clarke, F. E. Van Leeuwen, M. Henry-Amar, M. V. Fiorentino, J. Bell, D. Pedersen, P. Band & D. Assouline (1990). "Leukemia following Hodgkin's disease". The New England journal of medicine. 322 (1): 7–13. doi:10.1056/NEJM199001043220102. PMID 2403650. Unknown parameter |month= ignored (help)
  7. M. Henry-Amar (1992). "Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease". Annals of oncology : official journal of the European Society for Medical Oncology. 3 Suppl 4: 117–128. PMID 1450072. Unknown parameter |month= ignored (help)
  8. F. E. van Leeuwen, W. J. Klokman, M. B. Veer, A. Hagenbeek, A. D. Krol, U. A. Vetter, M. Schaapveld, P. van Heerde, J. M. Burgers, R. Somers & B. M. Aleman (2000). "Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18 (3): 487–497. doi:10.1200/JCO.2000.18.3.487. PMID 10653864. Unknown parameter |month= ignored (help)
  9. Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/diagnosis/?region=ab Accessed on September 16, 2015
  10. Hodgkin-lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/hodgkin-lymphoma/diagnosis/?region=ab Accessed on September 16, 2015
  11. 11.0 11.1 11.2 11.3 11.4 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.


Template:WikiDoc Sources